Form 6-K GSK PLC For: Dec 05
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of December 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GSK plc
(the 'Company')
Transfer of Treasury Shares
On 1 December 2022, the Company transferred 26,800,000 ordinary shares of 31 1/4 pence
each ("Ordinary
Shares") that
were held by the Company in treasury ("Treasury
Shares") to
JPMorgan Chase Bank, N.A. the depositary of the Company's American
depositary receipts ("ADR")
programme, to procure the issuance and transfer of 13,400,000 ADRs
of the Company to the GlaxoSmithKline (US) Trust (the
"Trust"),
to be used to satisfy awards granted under the Company's Deferred
Annual Bonus Plan, Performance Share Plan and Share Value
Plan. The consideration received from
the trustee of the Trust of $34.590 per ADR, representing $17.295
per Ordinary Share, was funded by a contribution to the Trust from
GlaxoSmithKline LLC.
Following the transfer and as at 2 December 2022, the Company's
issued share capital consisted of 4,311,323,691 Ordinary Shares, of
which 217,124,760 were held as Treasury Shares.
Therefore, the total number of voting rights in
the Company is 4,094,198,931. This figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure Guidance and Transparency
Rules.
Notifications may be sent to [email protected].
V A Whyte
Company Secretary
5 December 2022
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GSK plc
|
|
(Registrant)
|
|
|
Date: December
05, 2022
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|